What drove the 62.96% drop in 1332.HK stock on 23 Jan 2026?

The move was driven by extraordinary volume **533,662,844** versus average **5,119,456**, suggesting block selling or forced liquidations. No single public corporate announcement explained it at publication; check company filings and the Touyun Biotech site for updates.

How does Meyka AI view 1332.HK stock now?

Meyka AI rates 1332.HK at **60.17** (Grade B, HOLD). The score balances diversified business lines against weak liquidity and negative margins. This is informational and not investment advice.

What are realistic price targets for 1332.HK stock?

Meyka AI's model projects **HK$0.23** (monthly) and **HK$0.27** (quarterly); a conservative base case price target is **HK$0.15** and a bear case **HK$0.05**. Forecasts are model projections, not guarantees.

What risks should investors note for 1332.HK stock?

Key risks include low current ratio **0.20**, negative shareholders equity, long receivable days (DSO **200**), and volatile liquidity on the HKSE. These issues can amplify price moves in either direction.

HK Stocks

1332.HK falls 62.96% to HK$0.10 on 23 Jan 2026: assess liquidity pressures

ByDanny Kontos January 23, 2026January 23, 2026

1332.HK stock opened the session after a sharp sell-off and closed the Hong Kong market at HK$0.10, down 62.96% on 23 Jan 2026. The share rout came with a flood of volume at 533,662,844 shares versus an average of 5,119,456, marking Touyun Biotech Group Limited (1332.HK) among the day’s most active HKSE names. Traders should note the gap from the 50-day average price HK$0.27 and the company’s weak liquidity metrics. We break down what moved the price, where support may lie, and what our models and grade say about risk and potential reward.